Organization
Carolina BioOncology Institute
10 abstracts
Abstract
Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.Org: Stephenson Cancer Center, The Tisch Cancer Institute, Mayo Clinic Cancer Center Scottsdale, The University of Arizona Cancer Center, City of Hope Comprehensive Cancer Center,
Abstract
Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors.Org: Southern Oncology Clinical Research Unit Pty Ltd., Macquarie University, Cabrini Research, Alfred Health, Carolina BioOncology Institute,
Abstract
Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors.Org: START Midwest, Grand Rapids, MI, National Cancer Center Hospital East, Kashiwa, Japan, University of Colorado Cancer Center, Rambam Medical Center, Next Oncology Virginia and Virginia Cancer Specialists,
Abstract
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.Org: Sarah Cannon Research Institute at Florida Cancer Specialists, Hackensack Meridian Health, START San Antonio, University of Navarra, Carolina BioOncology Institute,
Abstract
A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors.Org: The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, a Cedars-Sinai Affiliate, Los Angeles, CA, Hackensack Meridian Health, Hackensack, NJ,
Abstract
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.Org: University of Okahoma Health Sciences Center, Carolina BioOncology Institute, Sarah Cannon Research Institute/Tennessee Oncology, University of Michigan, START Midwest, Grand Rapids, MI,
Abstract
Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors.Org: Carolina BioOncology Institute, Massachusetts General Hospital, Hackensack Meridian Health, Moderna Therapeutics, Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China,
Abstract
Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.Org: UPMC Hillman Cancer Center, Clear Lake Oncology, Next Oncology Virginia and Virginia Cancer Specialists, Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, Orlando, FL, Massachusetts General Hospital,
Abstract
Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation.Org: The Christ Hospital Health Network, Carolina BioOncology Institute, Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, UPMC Hillman Cancer Center, Tasman Oncology Research,
Abstract
A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: Interim results.Org: Monash Health, Bentleigh East, VIC, Australia, Monash University School of Public Health and Preventive Medicine, Southern Health, Austin Health, Alfred Hospital and Monash University,